Trial Profile
Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Neostigmine
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 01 Jun 2021 Primary endpoint (Time in Minutes to Reach Train of Four (TOF) Ratio 0.9 After the Administration of Reversal Agent) has been met as per results published in the Anesthesia and Analgesia
- 01 Jun 2021 Results published in the Anesthesia and Analgesia
- 12 Mar 2021 Status changed from active, no longer recruiting to completed.